Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00506597 · ClinicalTrials.gov registry record · NA

Erwinase Study in Patients With Acute Lymphoblastic Leukemia

A NA study of Leukemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT00506597 is a NA study of Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00506597, a NA study of Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. This trial was part of a multi institutional effort by the drug company to make Erwinase available for use.

Conditions Studied

Interventions

  • DRUG Erwinase

Study Locations (1)

Texas

  • UT MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2007-05
Est. Completion 2012-02
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00506597

The ClinicalTrials.gov registry entry for NCT00506597 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Erwinase is the first listed.

NCT00506597 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00506597 about?

NCT00506597 is a clinical study titled "Erwinase Study in Patients With Acute Lymphoblastic Leukemia". The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. ...

What is the current status of trial NCT00506597?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-05. Estimated completion is 2012-02.

What conditions does trial NCT00506597 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT00506597?

The interventions under investigation include: Erwinase (DRUG).

Who is sponsoring clinical trial NCT00506597?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00506597 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.